{
    "id": 10710,
    "fullName": "CDKN2B del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2B del indicates a deletion of the CDKN2B gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1030,
        "geneSymbol": "CDKN2B",
        "terms": [
            "CDKN2B",
            "CDK4I",
            "INK4B",
            "MTS2",
            "P15",
            "p15INK4b",
            "TP15"
        ]
    },
    "variant": "del",
    "createDate": "08/20/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2930,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Kisqali (ribociclib) inhibited proliferation of a Gleevec (imatinib)-resistant dermatofibroscarcoma cell line harboring deletion of both CDKN2A and CDKN2B and a PDGFB rearrangement (PMID: 25852058).",
            "molecularProfile": {
                "id": 10737,
                "profileName": "PDGFB fusion CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3535,
                    "pubMedId": 25852058,
                    "title": "CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25852058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9501,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Kisqali (ribociclib) demonstrated preliminary efficacy in patients with advanced solid tumors and lymphomas, and 2/4 CCND1-amplified patients remaining on treatment for greater than 8 weeks also had co-deletion of CDKN2A and CDKN2B (PMID: 27542767).",
            "molecularProfile": {
                "id": 26860,
                "profileName": "CCND1 amp CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7226,
                    "pubMedId": 27542767,
                    "title": "A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542767"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11541,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease for a total of 15 months in a pancreatic ductal adenocarcinoma patient harboring EML4-ALK, along with CDKN2A/B deletion, MYC amplification, and TP53 L111fs (PMID: 28476735).",
            "molecularProfile": {
                "id": 28129,
                "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17522,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Ibrance (palbociclib) in combination with Zelboraf (vemurafenib) resulted in clinical improvement and stable disease in a patient with epithelioid glioblastoma harboring BRAF V600E and homozygous deletion of CDKN2A and CDKN2B, however, his disease progressed after 10 weeks on treatment (PMID: 31217909).",
            "molecularProfile": {
                "id": 32674,
                "profileName": "BRAF V600E CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 4129,
                "therapyName": "Palbociclib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15565,
                    "pubMedId": 31217909,
                    "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10735,
            "profileName": "CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10737,
            "profileName": "PDGFB fusion CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26860,
            "profileName": "CCND1 amp CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28129,
            "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32674,
            "profileName": "BRAF V600E CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}